In vitro miltefosine and amphotericin B susceptibility of strains and clinical isolates of Leishmania species endemic in Brazil that cause tegumentary leishmaniasis

Imagem de Miniatura
Arquivos
art_FERREIRA_In_vitro_miltefosine_and_amphotericin_B_susceptibility_of_2023.PDF (1.66 MB)
Citações na Scopus
2
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ACADEMIC PRESS INC ELSEVIER SCIENCE
Autores
FERREIRA, Bianca A.
COSER, Elizabeth M.
SABORITO, Cristiele
COELHO, Adriano C.
Citação
EXPERIMENTAL PARASITOLOGY, v.246, article ID 108462, 7p, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Tegumentary leishmaniasis encompasses a spectrum of clinical manifestations caused by the parasitic protozoa of the genus Leishmania. In Brazil, there are at least seven Leishmania species that are endemic and responsible for this set of clinical manifestations of the disease. Current treatment is limited to a restricted number of drugs that in general have several drawbacks including parenteral use, toxicity, and severe side effects. Amphotericin B is considered a second-line drug for tegumentary leishmaniasis in Brazil, while miltefosine was recently approved for clinical use in the treatment of this disease. In this study, we investigated the in vitro susceptibility of Leishmania strains representative of the species endemic to Brazil, as well as a panel of thirteen clinical isolates of tegumentary leishmaniasis, to both amphotericin B and miltefosine. A moderate variation in the susceptibility to both drugs was found, where the EC50 values varied from 11.43 to 52.67 mu M for miltefosine and from 12.89 to 62.36 nM for amphotericin B in promastigotes, while for the intracellular amastigotes, values ranged from 1.08 to 9.60 mu M and from 1.69 to 22.71 nM for miltefosine and amphotericin B respectively. Furthermore, the clinical isolates and strains of the subgenus Viannia were evaluated for the presence of Leishmania RNA virus 1 (LRV1), as this is an important factor associated with disease severity and treatment outcome. These findings provide a preclinical dataset of the activity of these drugs against the causative species of tegumentary leishmaniasis in Brazil.
Palavras-chave
Amphotericin B, Drug susceptibility, Leishmania, Miltefosine, Tegumentary leishmaniasis
URI
https://observatorio.fm.usp.br/handle/OPI/53929
Referências
  1. Alpizar-Sosa EA, 2022, PLOS NEGLECT TROP D, V16, DOI 10.1371/journal.pntd.0010779
  2. Alvar J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035671
  3. Bhandari V., 2012, PLOS NEGLECT TROP D, VNeglected
  4. Bilbao-Ramos P, 2017, ACTA TROP, V176, P150, DOI 10.1016/j.actatropica.2017.07.026
  5. Burza S, 2018, LANCET, V392, P951, DOI 10.1016/S0140-6736(18)31204-2
  6. Cantanhede LM, 2019, PARASITE, V26, DOI 10.1051/parasite/2019030
  7. Cantanhede LM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198727
  8. Cantanhede LM, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004079
  9. Castellucci L, 2011, GENES IMMUN, V12, P589, DOI 10.1038/gene.2011.37
  10. Chrusciak-Talhari A, 2011, AM J TROP MED HYG, V84, P255, DOI 10.4269/ajtmh.2011.10-0155
  11. Cojean S, 2012, EMERG INFECT DIS, V18, P704, DOI 10.3201/eid1804.110841
  12. CONITEC, 2018, MILT TRAT LEISHM TEG, P34
  13. Coser EM, 2021, ACTA TROP, V215, DOI 10.1016/j.actatropica.2020.105806
  14. Decuypere S, 2005, ANTIMICROB AGENTS CH, V49, P4616, DOI 10.1128/AAC.49.11.4616-4621.2005
  15. Espada CR, 2019, INT J PARASITOL-DRUG, V11, P139, DOI 10.1016/j.ijpddr.2019.02.005
  16. Espada CR, 2017, AM J TROP MED HYG, V96, P656, DOI 10.4269/ajtmh.16-0811
  17. Fagundes-Silva GA, 2015, MEM I OSWALDO CRUZ, V110, P797, DOI 10.1590/0074-02760150128
  18. Goto H, 2010, EXPERT REV ANTI-INFE, V8, P419, DOI [10.1586/eri.10.19, 10.1586/ERI.10.19]
  19. Hartley MA, 2012, FRONT CELL INFECT MI, V2, DOI 10.3389/fcimb.2012.00099
  20. HOWARD MK, 1991, T ROY SOC TROP MED H, V85, P477, DOI 10.1016/0035-9203(91)90226-O
  21. Ives A, 2011, SCIENCE, V331, P775, DOI 10.1126/science.1199326
  22. KAPLER GM, 1990, MOL CELL BIOL, V10, P1084, DOI 10.1128/MCB.10.3.1084
  23. Kuhlmann FM, 2017, P NATL ACAD SCI USA, V114, pE811, DOI 10.1073/pnas.1619114114
  24. Machado PR, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000912
  25. Mbongo N, 1998, ANTIMICROB AGENTS CH, V42, P352
  26. Mondelaers A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154101
  27. Murray HW, 2005, LANCET, V366, P1561, DOI 10.1016/S0140-6736(05)67629-5
  28. Mwenechanya R, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005649
  29. Obonaga R, 2014, ANTIMICROB AGENTS CH, V58, P144, DOI 10.1128/AAC.01023-13
  30. Pan American Health Organization, 2021, LEISHM EP REP AM
  31. Ramos H, 1996, J MEMBRANE BIOL, V152, P65, DOI 10.1007/s002329900086
  32. Reithinger R, 2007, LANCET INFECT DIS, V7, P581, DOI 10.1016/S1473-3099(07)70209-8
  33. Rocio C, 2014, T ROY SOC TROP MED H, V108, P176, DOI 10.1093/trstmh/tru011
  34. SCHEFFTER S, 1994, VIROLOGY, V199, P479, DOI 10.1006/viro.1994.1149
  35. Silveira FT, 2004, MEM I OSWALDO CRUZ, V99, P239, DOI 10.1590/S0074-02762004000300001
  36. Silveiraa FT, 2019, T ROY SOC TROP MED H, V113, P505, DOI 10.1093/trstmh/trz037
  37. Solomon M, 2007, J AM ACAD DERMATOL, V56, P612, DOI 10.1016/j.jaad.2006.06.044
  38. Uliana SRB, 2018, PARASITOLOGY, V145, P464, DOI 10.1017/S0031182016002523
  39. Yardley V, 2005, AM J TROP MED HYG, V73, P272, DOI 10.4269/ajtmh.2005.73.272
  40. Yardley V, 2006, J INFECT DIS, V194, P1168, DOI 10.1086/507710
  41. Zamboni DS, 2003, INFECT IMMUN, V71, P1225, DOI 10.1128/IAI.71.3.1225-1233.2003
  42. Zauli-Nascimento R.C., 2010, TROP MED INT HEALTH
  43. Zulfigar B, 2017, DRUG DISCOV TODAY, V22, P1516, DOI 10.1016/j.drudis.2017.06.004

Coleções
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - IMT
Artigos e Materiais de Revistas Científicas - LIM/48
Artigos e Materiais de Revistas Científicas - LIM/49